What is ACXP stock price today?

ACXP (Acurx Pharmaceuticals LLC) stock is trading at $2.57 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ACXP stock going up or down today?

ACXP stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ACXP stock now?

The decision to buy ACXP depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ACXP a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ACXP based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ACXP stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ACXP is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ACXP's P/E ratio?

P/E ratio data for ACXP will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ACXP's market cap?

ACXP (Acurx Pharmaceuticals LLC) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is ACXP's price to book ratio?

ACXP trades at a price-to-book (P/B) ratio of 1.71, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ACXP pay dividends?

ACXP does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ACXP's dividend yield?

ACXP does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ACXP stock a good long-term investment?

ACXP's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ACXP's revenue growth rate?

Revenue growth data for ACXP is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ACXP are available on our dashboard with complete income statement analysis.

What are the risks of investing in ACXP?

Key risks for ACXP include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ACXP compare to its competitors?

Compare ACXP to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ACXP's performance and positioning.

What is ACXP's stock price target for 2026?

Our AI model provides price targets for ACXP based on fundamental analysis: Bull case $3.34 (+30%), Base case $2.96 (+15%), Bear case $2.31 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ACXP?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ACXP. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ACXP's next earnings report?

ACXP reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ACXP - Acurx Pharmaceuticals LLC

NYSE * Healthcare * Biotechnology

$2.57

$-0.08 (-2.94%)

About Acurx Pharmaceuticals LLC

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

ACXP Key Statistics

Market Cap

$6.22M

P/B Ratio

1.71

EPS

$-8.18

Employees

How ACXP Compares to Peers

ACXP is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ACXP(This stock)	$6.22M	N/A	0%	0.0%	-
AMGNAmgen Inc	$177.92B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.16B	31.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.12B	15.0	0%	0.2%	vs BIIB

Acurx Pharmaceuticals LLC Company Information

Headquarters: 259 Liberty Avenue, Staten Island, NY, United States, 10305, undefined
Website: www.acurxpharma.com
Sector: Healthcare
Industry: Biotechnology

ACXP - Acurx Pharmaceuticals LLC

About Acurx Pharmaceuticals LLC

ACXP Key Statistics

How ACXP Compares to Peers

Acurx Pharmaceuticals LLC Company Information

ACXP Lician Score

ACXP Financial Snowflake

Upcoming Events for ACXP